Estée Lauder
No proof required
Up to $5,000
Claims opening soon
B
Bristol-Myers Squibb
Bristol-Myers Squibb settled a $10 million antitrust class action involving Evotaz and Atripla HIV drugs.
ClosedUnited States-wideClaim status: Closed on June 27, 2022Payout: VariesNo longer claimable
About this settlement
The settlement addresses alleged antitrust violations affecting the cost of Evotaz and Atripla HIV medications.
This settlement resolves antitrust claims against Bristol-Myers Squibb related to the pricing of Evotaz and Atripla HIV drugs. Eligible claimants include patients and purchasers who paid for these drugs during the specified period.
Who qualifies
- Patients, purchasers, or entities who paid for brand-name or generic Evotaz or Atripla.
- Payments made between May 14, 2015 and October 13, 2021.
Varies
Claim status: Closed on June 27, 2022
Silk and Great Value
Proof required
Up to $300,000
95 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
745 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon